Oryzon Genomics (ORY) Q4 2025 earnings summary

Executive summary

• Ended 2025 with a strong cash position of $33.3 million, following a financial turnaround earlier in the year.

• Advanced two lead programs: iadademstat in oncology/hematology and vafidemstat in CNS disorders, with multiple ongoing and planned clinical trials.

• Appointed Dr. Rolando Gutierrez-Esteinou as Chief Medical Officer for CNS, enhancing regulatory and clinical leadership.

Financial highlights

• R&D expenses rose to $14.8 million for 2025, up from $8.7 million in 2024.

• General and administrative expenses increased to $5.6 million for 2025, compared to $3.7 million in 2024.

• Net loss for 2025 was $6.7 million, compared to $4.6 million in 2024.

• Cash and equivalents at year-end 2025 totaled $33.3 million, up from $5.8 million at the end of 2024.

• Total assets increased to $169.8 million at December 31, 2025, from $114.1 million a year earlier.

Outlook and guidance

• Plans to present interim data from the ongoing AML trial at EHA in June 2026, representing about 75% of planned enrollment.

• Expects to report meaningful data from the sickle cell disease RESTORE trial later in 2026.

• Anticipates resubmission of the Phase III PORTICO-2 protocol for vafidemstat in BPD before year-end 2026.